NCT00225979View on ClinicalTrials.gov

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Acromegaly
Interventions
DRUG

Octreotide LAR

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00225979 - Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly | Biotech Hunter | Biotech Hunter